|Awarded On||August 18, 2021|
|Title||Multiplex CRISPR genetic modeling of polypharmacology for precision medicine|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Traver Hart|
|Cancer Sites||All Sites|
*Pending contract negotiation
Matching the right drug to the right tumor requires integrating tumor genotype with preclinical research about the relationship between genetic mutation and drug response. The successes of Gleevec (imatinib) against BCR-ABL leukemias, and Herceptin (trastuzamab) in HER2+ breast cancer, are testament to the power of this approach. To broaden this knowledge base, we developed CRISPR-based gene knockout screens to identify putative chemotherapeutic targets in cancer cells. To date, nearly one thousand cell lines from more than thirty different tumor lineages have been screened using this CRISPR-mediated approach, and several genotype-specific vulnerabilities have been discovered and validated....